13G Filing: James E. Flynn and Biocryst Pharmaceuticals Inc (BCRX)

Page 5 of 14

Page 5 of 14 – SEC Filing

CUSIP No. 09058V103 13G Page 5
of 11 Pages
1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield International Master Fund, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b) ☒

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

2,860,732 (4)

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

2,860,732 (4)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,860,732 (4)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES*

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

3.56%

12.

TYPE OF REPORTING PERSON*

PN

(4) Includes options to purchase 280,000 shares of common stock.

Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)

Page 5 of 14